Construction and characterization of a novel chimeric antibody c3C7 specific for the integrin αIIbβ3 complex.

In conclusion, after the modification, c3C7 retained the properties of its parent mAb with no loss of its biological activity. Therefore, c3C7 has the potential to become a novel agent for the treatment of thrombosis.
PMID: 24113827 [PubMed - as supplied by publisher]

Source: Applied Microbiology and Biotechnology - October 11, 2013 Category: Microbiology Authors: Jiang A, Zhang W, Wu Q, Jin W, Tang Y, Zhang J, Liu JN Tags: Appl Microbiol Biotechnol Source Type: research